retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Retatrutide | GLP-1R/GIPR/GCGR ligand |
Description
The aim of this article is to discuss CVOTs involving GLP-1 receptor agonists and their impact on cardiovascular risk
The potentiation of insulin action by d-allulose was blocked by treatment with 200 nmol kg 1 Ex(9-39) (Fig
Wegovy is especially approved for weight loss, making it a highly effective obesity treatment, whereas Ozempic is generally used for type 2 diabetes
doi:10.1038/s41467-023-44067-4 207
Nobody knew where it would lead, and several of the participants are unfortunately now deceased
Expert Rev Endocrinol Metab 2025;20:147-52.ArticlePubMed 96
